Meeting Report

Modern Management of Classical Hodgkin Lymphoma

Presented by Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD

Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland; and Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Tampa, Florida

Presenters’ disclosures of conflicts of interest are found at the end of this article.

ABSTRACT

Thanks to the introduction of checkpoint inhibitors, patients with classical Hodgkin lymphoma have a better chance at living longer with the disease. However, treatment-related side effects can impact quality of life in the short- and long-term. Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD, provided strategies for preventing and mitigating these adverse events.

For access to the full length article, please sign in.